header.html

An official website of the European Union How do you know?      
European Commission logo

handle.jsp

cover
Targeted alpha therapy (TAT) plays an important role in palliative as well as curative treatment of patients with oncological diseases. Several radionuclides suitable for TAT are decaying by emission of an α-particle cascade, which can on one hand improve therapeutic outcome, but on the other hand also cause severe damage to non-target tissues. One strategy to at least partially reduce this progeny spread over the body is based on the use of nanoparticles (NPs). The aim of this work was to determine the fraction of recoiling atoms activity originating from 225Ac decay (221Fr, 213Bi) and study the progeny wash-out dependence over time and on the concentration of TiO2 NPs as a potential carrier of radionuclides for TAT.
2022-12-16
SPRINGER
JRC129439
1619-7070 (online),   
https://publications.jrc.ec.europa.eu/repository/handle/JRC129439,   
10.1007/s00259-022-05924-4 (online),   
NameCountryCityType
Datasets
IDTitlePublic URL
Dataset collections
IDAcronymTitlePublic URL
Scripts / source codes
DescriptionPublic URL
Additional supporting files
File nameDescriptionFile type 

footer.html